Eli Lilly (LLY) Total Liabilities (2009 - 2026)

Eli Lilly has reported Total Liabilities for 18 years, with the latest figure at $85.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 14.93% year-over-year to $85.4 billion; the trailing twelve-month figure through Mar 2026 stood at $85.4 billion (up 14.93% YoY), and the FY2025 full-year result was $85.9 billion, up 5.96% from the prior year.
• Total Liabilities for Q1 2026 stood at $85.4 billion, down from $85.9 billion in the prior quarter.
• The five-year high for Total Liabilities was $103.1 billion in Q2 2025, with the low at $49.5 billion in Q1 2022.
• Historically, Total Liabilities has averaged $68.6 billion across 5 years, with a median of $66.7 billion in 2023.
• Annual changes were most pronounced in 2022 — Total Liabilities rose 0.18% — and 2025, when it jumped 43.4%.
• Eli Lilly's Total Liabilities stood at $53.3 billion in 2022, then gained by 25.07% to $66.7 billion in 2023, then increased by 21.59% to $81.1 billion in 2024, then climbed by 5.96% to $85.9 billion in 2025, then dropped by 0.66% to $85.4 billion in 2026.
• The last three Total Liabilities figures came in at $85.4 billion (Q1 2026), $85.9 billion (Q4 2025), and $91.1 billion (Q3 2025), per Business Quant data.